What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2021-05-19 compared with 2020-06-12 · 668 added, 806 removed, 121 unchanged (92% of the section changed)

Market for the

Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information for Common Stock

Our common stock was

listed on the Nasdaq Capital Market under the symbol “AMMA”

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Information for Common Stock

common stock was listed on the Nasdaq Capital Market under the symbol “AMMA”

from October 6, 2016 through February

was changed to “WORX”

Our symbol was changed to “WORX”

on February 4, 2019 in connection with the closing of the SCWorx acquisition.

The following table

sets forth for the indicated periods the high and low closing prices for SCWorx’s common stock as reported on the NASDAQ

Capital Market.

First Quarter

Second Quarter

Third Quarter

Fourth Quarter

Holders of Record

As of June 3, 2020, there

were 9,385,582 outstanding shares of common stock held by 109 stockholders of record.

We have never declared

or paid any cash dividends on our shares of common stock, and we do not expect to pay cash dividends in the foreseeable future.

We anticipate that we will retain any earnings to support operations and to finance the growth and development of our business.

Any future determination relating to our dividend policy will be made at the discretion of our Board of Directors and will depend

on a number of factors, including future earnings, capital requirements, financial conditions and future prospects and other factors

the Board of Directors may deem relevant.

Furthermore, our ability to pay dividends is limited by the Delaware General Corporation

Law, which provides that a corporation may pay dividends only out of existing “surplus,”

which is defined as the amount

by which a corporation’s net assets exceeds its stated capital.

Refer to Note 10, Stockholders’

Equity, in the accompanying consolidated financial statements for a non–cash dividend related to the decrease in the exercise

price of certain warrants.

The following table sets forth for the indicated periods the high and low closing prices for SCWorx’s common stock as reported

on the NASDAQ Capital Market.

January 4, 2021, The Nasdaq Stock Market notified us that due to our failure to hold our annual meeting before December 31, 2020,

we were no longer in compliance with their listing rule which requires us to hold our annual meeting before December 31 of each

The Company intends to hold a Special Meeting in lieu of its 2020 Annual Meeting in May 2021, which will have the effect

of curing this deficiency.

Further on April 19, 2021 and April 21, 2021, the Nasdaq Stock Market

notified the Company that it was not in compliance with the Nasdaq’s rules for continued listing because the Company has not yet

filed its 10-K for the fiscal year ended December 31, 2020 (“2020 10-K”), as required by Nasdaq Rule 5250(c)(1) (the April

21 notification superseded the April 19 notification).

The most recent Nasdaq notice requires the Company to submit its plan to regain

compliance, no later than May 19, 2021.

The filing of this 10-K will cure this deficiency.

of May 15, 2021, there were 10,029,433 outstanding shares of common stock held by 86 stockholders of record.

have never declared or paid any cash dividends on our shares of common stock, and we do not expect to pay cash dividends in the

foreseeable future.

We anticipate that we will retain any earnings to support operations and to finance the growth and development

of our business.

Any future determination relating to our dividend policy will be made at the discretion of our Board of Directors

and will depend on a number of factors, including future earnings, capital requirements, financial conditions and future prospects

and other factors the Board of Directors may deem relevant.

Furthermore, our ability to pay dividends is limited by the Delaware

General Corporation Law, which provides that a corporation may pay dividends only out of existing “surplus,”

is defined as the amount by which a corporation’s net assets exceeds its stated capital.

to Note 9, Stockholders’

Equity, in the accompanying consolidated financial statements for a non–cash dividend related

to the decrease in the exercise price of certain warrants.

Selected Financial Data

Not required under Regulation S-K for “smaller

reporting companies.”

Management’s Discussion and Analysis of Financial

Condition and Results of Operations

This Management’s Discussion

and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Management’s

current views with respect to future events and financial performance.

You can identify these statements by forward-looking words

such as “may”

required under Regulation S-K for “smaller reporting companies.”

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking

statements that reflect Management’s current views with respect to future events and financial performance.

You can identify

these statements by forward-looking words such as “may”

“will,”

5 unchanged sentences

or similar words.

Those statements include statements regarding the intent, belief or current expectations

of us and members of our management team as well as the assumptions on which such statements are based.

Prospective investors

are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties,

and that actual results may differ materially from those contemplated by such forward-looking statements.

Readers are urged to carefully review

and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange

Important factors known to us could cause actual results to differ materially from those in forward-looking statements.

We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated

events or changes in the future operating results over time.

We believe that its assumptions are based upon reasonable data derived

from and known about our business and operations and the business and operations of our company.

No assurances are made that actual

results of operations or the results of our future activities will not differ materially from its assumptions.

Factors that could

cause differences include, but are not limited to, expected market demand for our services, fluctuations in pricing for materials,

and competition.

On February 1, 2019, we

acquired SCWorx Corp.

in a stock for stock transaction, in connection with which we changed our name to SCWorx Corp.

our trading symbol on the Nasdaq to WORX.

SCWorx is a leading provider of data content and services related to the repair, normalization

and interoperability of information for healthcare providers and big data analytics for the healthcare industry.

SCWorx has developed and

markets health information technology solutions and associated services that improve healthcare processes and information flow

within hospitals.

SCWorx’s software platform enables healthcare providers to simplify, repair, and organize its data (“data

normalization”), allows the data to be utilized across multiple internal software applications (“interoperability”)

Those statements include statements

regarding the intent, belief or current expectations of us and members of our management team as well as the assumptions on which

such statements are based.

Prospective investors are cautioned that any such forward-looking statements are not guarantees of

future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by

such forward-looking statements.

are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with

the Securities and Exchange Commission.

Important factors known to us could cause actual results to differ materially from those

in forward-looking statements.

We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions,

the occurrence of unanticipated events or changes in the future operating results over time.

We believe that its assumptions are

based upon reasonable data derived from and known about our business and operations and the business and operations of our company.

No assurances are made that actual results of operations or the results of our future activities will not differ materially from

its assumptions.

Factors that could cause differences include, but are not limited to, expected market demand for our services,

fluctuations in pricing for materials, and competition.

February 1, 2019, we acquired SCWorx Corp.

in a stock for stock transaction, in connection with which we changed our name to SCWorx

and changed our trading symbol on the Nasdaq to WORX.

SCWorx is a leading provider of data content and services related

to the repair, normalization and interoperability of information for healthcare providers and big data analytics for the healthcare

has developed and markets health information technology solutions and associated services that improve healthcare processes and

information flow within hospitals.

SCWorx’s software platform enables healthcare providers to simplify, repair, and organize

its data (“data normalization”), allows the data to be utilized across multiple internal software applications (“interoperability”)

and provides the basis for sophisticated data analytics (“big data”).

5 unchanged sentences

and cost visibility, synchronous charge description master (“CDM”) and control of vendor rebates and contract administration

SCWorx empowers healthcare

providers to maintain comprehensive access and visibility to an advanced business intelligence that enables better decision-making

and reductions in product costs and utilization, ultimately leading to accelerated and accurate patient billing.

SCWorx’s

software modules perform separate functions as follows:

● virtualized Item Master File repair, expansion and automation;

● CDM management;

● contract management;

● request for proposal automation;

● rebate management;

● big data analytics modeling;

● data integration and warehousing.

SCWorx continues to

provide transformational data-driven solutions to many healthcare providers in the United States.

The Company’s clients

are geographically dispersed throughout the country.

The Company’s focus is to assist healthcare providers with issues that

they have pertaining to data interoperability.

SCWorx provides these solutions through a combination of direct sales and relationships

with strategic partners.

SCWorx’s software

solutions are delivered to its clients within a fixed term period, typically a three-to-five-year contracted term, where such software

is hosted in SCWorx data centers (Amazon Web Service’s “AWS”

or RackSpace) and accessed by such clients through

a secure connection in a software as a service (“SaaS”) delivery method.

SCWorx currently sells

its solutions and services in the United States to hospitals and health systems through its direct sales force and its distribution

and reseller partnerships.

Direct-Worx —

In March 2020, in response to the COVID-19 pandemic, SCWorx established a wholly-owned subsidiary, Direct-Worx, LLC, which will

utilize the SCWorx database to identify trends within the purchasing supply chain and use this information to source and provide

critical, difficult-to-find items for the healthcare industry.

Items are becoming increasingly difficult to source due to

unexpected disruptions within the supply chain, such as the COVID-19 pandemic.

These products currently include:

Test Kits —

Company has identified multiple potential sources for Rapid Test Kits for COVID-19.

Protective Equipment (PPE) includes items such as masks, gloves, gowns, shields, etc.

The Company has extensive experience and

a database of items specifically designated to assist the healthcare industry in fulfilling its inventory demands.

The sale of PPE and

rapid test kits for COVID-19 represent a new business for the Company and is subject to the myriad risks associated with any new

The Company has for example encountered great difficulty in attempting to secure reliable sources of supply for both

COVID-19 Rapid Test Kits and PPE including, 3M N95 masks, which are the preferred medical grade mask of US healthcare companies.

Further, the Company has encountered shipping delays with regard to masks and other PPE, and significant quality related issues

regarding N95 masks.

In addition, regarding its sourcing of COVID-19 Rapid Test Kits, the Company has encountered significant

shipping delays, as well as reduced quantities.

Consequently, there is no assurance as to the timing or quantities of any future

deliveries of COVID-19 Test Kits.

The Company has yet to complete the sale of any COVID-19 rapid test kits and had no test kits

or PPE in inventory as of December 31, 2019 and had 19,000 test kit units as of the date of this report.

In addition, changes

in FDA processes governing the sale of COVID-19 serology tests could have the effect of rendering the COVID-19 serology tests

to be sold by the Company not saleable in the United States, which could have a material adverse effect on the Company.

See Government

The Company intends to begin selling COVID-19 rapid test kits in 2020.

There can be no assurance that the Company

will be able to generate any significant revenue from the sale of PPE products or rapid test kits.

SCWorx, as a result

of the acquisition, also operates an online event ticketing platform focused on serving regional mixed martial arts promotions.

Due to the relative size of the ticketing business and how information is reported to the Company’s chief operating decision

maker, the Company includes such ticketing business as part of its SaaS business reporting unit.

empowers healthcare providers to maintain comprehensive access and visibility to an advanced business intelligence that enables

better decision-making and reductions in product costs and utilization, ultimately leading to accelerated and accurate patient

SCWorx’s software modules perform separate functions as follows:

Item Master File repair, expansion and automation;

for proposal automation;

data analytics modeling;

integration and warehousing.

continues to provide transformational data-driven solutions to many healthcare providers in the United States.

The Company’s

SaaS business is focused on streamlining three core healthcare provider systems;

supply chain, financial and clinical enabling

providers’

enterprise systems to work as one automated and seamless business management system.

SCWorx offers an advanced

software solution for the management of health care providers’

foundational business applications, empowering its customers

to significantly reduce costs, drive better clinical outcomes and enhance such providers’

SCWorx supports the interrelationship

between the three above-referenced core healthcare provider systems.

This solution moves data from one application to another to

drive supply cost reductions, optimize contracts, increase supply chain management cost visibility and control rebates and contract

administration fees.

Critical Accounting Policies and Estimates

clients are geographically dispersed throughout the country.

The Company’s focus is to assist healthcare providers with

issues that they have pertaining to data interoperability.

SCWorx provides these solutions through a combination of direct sales

and relationships with strategic partners.

SCWorx’s

software solutions are delivered to its clients within a fixed term period, typically a three-to-five-year contracted term, where

such software is hosted in SCWorx data centers (Amazon Web Service’s “AWS”

or RackSpace) and accessed by such

clients through a secure connection in a software as a service (“SaaS”) delivery method.

currently sells its solutions and services in the United States to hospitals and health systems through its direct sales force

and its distribution and reseller partnerships.

SCWorx, as part of the acquisition of Alliance MMA, operated an online

event ticketing platform focused on serving regional MMA (“mixed martial arts”) promotions.

currently host our solutions, serve our customers, and support our operations in the United States through an agreement with a

third party hosting and infrastructure provider, RackSpace.

We incorporate standard IT security measures, including but not limited

firewalls, disaster recovery, backup, etc.

Our operations are dependent upon the integrity, security and consistent operation

of various information technology systems and data centers that process transactions, communication systems and various other

software applications used throughout our operations.

Disruptions in these systems could have an adverse impact on our operations.

We could encounter difficulties in developing new systems or maintaining and upgrading existing systems.

Such difficulties could

lead to significant expenses or to losses due to disruption in our business operations.

addition, our information technology systems are subject to the risk of infiltration or data theft.

The techniques used to obtain

unauthorized access, disable or degrade service, or sabotage information technology systems change frequently and may be difficult

to detect or prevent over long periods of time.

Moreover, the hardware, software or applications we develop or procure from third

parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our

information systems.

Unauthorized parties may also attempt to gain access to our systems or facilities through fraud or deception

aimed at our employees, contractors or temporary staff.

In the event that the security of our information systems is compromised,

confidential information could be misappropriated, and system disruptions could occur.

Any such misappropriation or disruption

could cause significant harm to our reputation, lead to a loss of sales or profits or cause us to incur significant costs to reimburse

third parties for damages.

Accounting Policies and Estimates

Management’s

15 unchanged sentences

of our accounting policies.

Basis of Presentation

The accompanying consolidated

financial statements have been prepared in accordance to U.S.

GAAP and the rules and regulations of the U.S.

Securities and Exchange

Commission (“SEC”).

The accompanying consolidated financial statements include the accounts of SCWorx and its wholly-owned

subsidiaries.

All material intercompany balances and transactions have been eliminated in consolidation.

Principles of Consolidation

The accompanying consolidated

financial statements include the accounts of the Company and its wholly-owned subsidiaries.

All material intercompany balances

and transactions have been eliminated in consolidation.

Reverse Stock Split

On February 1, 2019,

we effected a 1-for-19 reverse stock split with respect to the outstanding shares of our common stock.

The reverse stock split

was deemed effective at the open of business on February 4, 2019.

The reverse stock split did not affect the total number of shares

of common stock that we are authorized to issue, which is 45,000,000 shares.

The reverse stock split also did not affect the total

number of shares of Series A preferred stock that we are authorized to issue, which is 900,000 shares.

Share and per share data

have been adjusted for all periods presented to reflect the reverse stock split unless otherwise noted.

Cash is maintained

with various financial institutions.

Financial instruments that potentially subject us to concentrations of credit risk consist

principally of cash deposits.

Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000.

Fair Value of Financial Instruments

Management applies

fair value accounting for significant financial assets and liabilities and non-financial assets and liabilities that are recognized

or disclosed at fair value in the consolidated financial statements on a recurring basis.

Management defines fair value as the

price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants

at the measurement date.

When determining the fair value measurements for assets and liabilities, which are required to be recorded

at fair value, management considers the principal or most advantageous market in which we would transact and the market-based risk

measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation

techniques, transfer restrictions and credit risk.

Fair value is estimated by applying the following hierarchy, which prioritizes

the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level

of input that is available and significant to the fair value measurement:

Level 1 - Quoted prices in active markets for identical

assets or liabilities.

Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities,

quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be

corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Inputs that are

generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing

the asset or liability.

Concentration of Credit and Other Risks

Financial instruments

that potentially subject our company to significant concentrations of credit risk consist principally of cash, accounts receivable

and warrants.

We believe that any concentration of credit risk in its accounts receivable is substantially mitigated by our evaluation

process, relatively short collection terms and the high level of credit worthiness of its customers.

We perform ongoing internal

credit evaluations of its customers’

financial condition, obtain deposits and limit the amount of credit extended when deemed

necessary but generally require no collateral.

For the year ended

December 31, 2019, we had two customers representing 19% and 10% of aggregate revenues.

For the year ended December 31, 2018, we

had three customers representing 20%, 16% and 12% of aggregate revenues.

At December 31, 2019, we had four customers representing

of Presentation

accompanying consolidated financial statements have been prepared in accordance to U.S.

GAAP and the rules and regulations of

Securities and Exchange Commission (“SEC”).

The accompanying consolidated financial statements include the

accounts of SCWorx and its wholly-owned subsidiaries.

All material intercompany balances and transactions have been eliminated

in consolidation.

of Consolidation

accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.

intercompany balances and transactions have been eliminated in consolidation.

February 1, 2019, we effected a 1-for-19 reverse stock split with respect to the outstanding shares of our common stock.

stock split was deemed effective at the open of business on February 4, 2019.

The reverse stock split did not affect the total

number of shares of common stock that we are authorized to issue, which is 45,000,000 shares.

The reverse stock split also did

not affect the total number of shares of Series A preferred stock that we are authorized to issue, which is 900,000 shares.

and per share data have been adjusted for all periods presented to reflect the reverse stock split unless otherwise noted.

is maintained with various financial institutions.

Financial instruments that potentially subject us to concentrations of credit

risk consist principally of cash deposits.

Accounts at each institution are insured by the Federal Deposit Insurance Corporation

up to $250,000.

Value of Financial Instruments

applies fair value accounting for significant financial assets and liabilities and non-financial assets and liabilities that are

recognized or disclosed at fair value in the consolidated financial statements on a recurring basis.

Management defines fair value

as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market

participants at the measurement date.

When determining the fair value measurements for assets and liabilities, which are required

to be recorded at fair value, management considers the principal or most advantageous market in which we would transact and the

market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks

inherent in valuation techniques, transfer restrictions and credit risk.

Fair value is estimated by applying the following hierarchy,

which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon

the lowest level of input that is available and significant to the fair value measurement:

Level 1 - Quoted prices in active markets

for identical assets or liabilities.

Level 2 - Observable inputs other than quoted prices in active markets for identical assets

and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable

or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Inputs

that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would

use in pricing the asset or liability.

Concentration

of Credit and Other Risks

instruments that potentially subject our company to significant concentrations of credit risk consist principally of cash, accounts

receivable and warrants.

We believe that any concentration of credit risk in its accounts receivable is substantially mitigated

by our evaluation process, relatively short collection terms and the high level of credit worthiness of its customers.

ongoing internal credit evaluations of its customers’

financial condition, obtain deposits and limit the amount of credit

extended when deemed necessary but generally require no collateral.

the year ended December 31, 2020, we had two customers representing 22% and 17% of aggregate revenues.

For the year ended December

31, 2019, we had two customers representing 19% and 10% of aggregate revenues.

At December 31, 2020, we had three customers representing

35%, 32% and 10% of aggregate accounts receivable.

At December 31, 2018, we had three customers representing 39%, 21% and

At December 31, 2019, we had four customers representing 17%, 14%, 10% and

10% of aggregate accounts receivable.

Allowance for Doubtful Accounts

Our company continually

monitors customer payments and maintains a reserve for estimated losses resulting from our customers’

inability to make required

In determining the reserve, we evaluate the collectability of our accounts receivable based upon a variety of factors.

In cases where we become aware of circumstances that may impair a specific customer’s ability to meet its financial obligations,

we record a specific allowance against amounts due.

For all other customers, we recognize allowances for doubtful accounts based

on our historical write-off experience in conjunction with the length of time the receivables are past due, customer creditworthiness,

geographic risk and the current business environment.

Actual future losses from uncollectible accounts may differ from our estimates.

The Company recorded an allowance for doubtful accounts as of December 31, 2019 and 2018 of $344,412 and $0, respectively.

We determine if an

arrangement is a lease at inception.

The current portion of lease obligations are included in accounts payable and accrued liabilities

on the consolidated balance sheets.

Right-of-use (“ROU”) assets represent our right to use an underlying asset for

the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease.

Operating lease ROU

assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term.

most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at

commencement date in determining the present value of lease payments.

Our lease terms may include options to extend or terminate

the lease, which are included in the lease ROU asset when it is reasonably certain that we will exercise that option.

Lease expense

for lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements with lease components only,

none with non-lease components, which are generally accounted for separately.

Business Combinations

Our company includes

the results of operations of a business we acquire in our consolidated results as of the date of acquisition.

We allocate the fair

value of the purchase consideration of our acquisition to the tangible assets, liabilities and intangible assets acquired, based

on their estimated fair values.

The excess of the fair value of purchase consideration over the fair values of these identifiable

assets and liabilities is recorded as goodwill.

The primary items that generate goodwill include the value of the synergies between

the acquired businesses and our company.

Intangible assets are amortized over their estimated useful lives.

The fair value of contingent

consideration (earn out) associated with acquisitions is remeasured each reporting period and adjusted accordingly.

and integration related costs are recognized separately from the business combination and are expensed as incurred.

For additional

information regarding our acquisitions, refer to Note 5, Business Combinations.

Goodwill and Identified Intangible Assets

Goodwill is recorded

as the difference between the aggregate consideration paid for an acquisition and the fair value of the net tangible and identified

intangible assets acquired under a business combination.

Goodwill also includes acquired assembled workforce, which does not qualify

as an identifiable intangible asset.

Management reviews impairment of goodwill annually in the fourth quarter, or more frequently

if events or circumstances indicate that the goodwill might be impaired.

We first assess qualitative factors to determine whether

it is necessary to perform the quantitative goodwill impairment test.

If, after assessing the totality of events or circumstances,

we determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then

the quantitative goodwill impairment test is unnecessary.

Identified intangible assets

Identified finite-lived

intangible assets consist of ticketing software and promoter relationships resulting from the February 1, 2019 business combination.

Our identified intangible assets are amortized on a straight-line basis over their estimated useful lives, ranging from 5 to 7

Management makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate

that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable.

facts and circumstances exist, we assess recoverability by comparing the projected undiscounted net cash flows associated with

the related asset or group of assets over their remaining lives against their respective carrying amounts.

Impairments, if any,

are based on the excess of the carrying amount over the fair value of those assets.

for Doubtful Accounts

company continually monitors customer payments and maintains a reserve for estimated losses resulting from our customers’

inability to make required payments.

In determining the reserve, we evaluate the collectability of our accounts receivable based

upon a variety of factors.

In cases where we become aware of circumstances that may impair a specific customer’s ability

to meet its financial obligations, we record a specific allowance against amounts due.

For all other customers, we recognize allowances

for doubtful accounts based on our historical write-off experience in conjunction with the length of time the receivables are

past due, customer creditworthiness, geographic risk and the current business environment.

Actual future losses from uncollectible

accounts may differ from our estimates.

The Company recorded an allowance for doubtful accounts as of December 31, 2020 and 2019

of $183,277 and $344,412, respectively.

determine if an arrangement is a lease at inception.

The current portion of lease obligations are included in accounts payable

and accrued liabilities on the consolidated balance sheets.

Right-of-use (“ROU”) assets represent our right to use

an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the

Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments

over the lease term.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the

information available at commencement date in determining the present value of lease payments.

Our lease terms may include options

to extend or terminate the lease, which are included in the lease ROU asset when it is reasonably certain that we will exercise

Lease expense for lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements

with lease components only, none with non-lease components, which are generally accounted for separately.

company includes the results of operations of a business we acquire in our consolidated results as of the date of acquisition.

We allocate the fair value of the purchase consideration of our acquisition to the tangible assets, liabilities and intangible

assets acquired, based on their estimated fair values.

The excess of the fair value of purchase consideration over the fair values

of these identifiable assets and liabilities is recorded as goodwill.

The primary items that generate goodwill include the value

of the synergies between the acquired businesses and our company.

Intangible assets are amortized over their estimated useful

The fair value of contingent consideration (earn out) associated with acquisitions is remeasured each reporting period

and adjusted accordingly.

Acquisition and integration related costs are recognized separately from the business combination and

are expensed as incurred.

For additional information regarding our acquisitions, refer to Note 5, Business Combinations.

and Identified Intangible Assets

is recorded as the difference between the aggregate consideration paid for an acquisition and the fair value of the net tangible

and identified intangible assets acquired under a business combination.

Goodwill also includes acquired assembled workforce, which

does not qualify as an identifiable intangible asset.

Management reviews impairment of goodwill annually in the fourth quarter,

or more frequently if events or circumstances indicate that the goodwill might be impaired.

We first assess qualitative factors

to determine whether it is necessary to perform the quantitative goodwill impairment test.

If, after assessing the totality of

events or circumstances, we determine that it is not more likely than not that the fair value of a reporting unit is less than

its carrying amount, then the quantitative goodwill impairment test is unnecessary.

intangible assets

finite-lived intangible assets consist of ticketing software and promoter relationships resulting from the February 1, 2019 business

Our identified intangible assets are amortized on a straight-line basis over their estimated useful lives, ranging

from 5 to 7 years.

Management makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances

indicate that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable.

If such facts and circumstances exist, we assess recoverability by comparing the projected undiscounted net cash flows associated

with the related asset or group of assets over their remaining lives against their respective carrying amounts.

Impairments, if

any, are based on the excess of the carrying amount over the fair value of those assets.

If the useful life is shorter than originally

estimated, we would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life.

For further discussion

of goodwill and identified intangible assets, refer to Note 5, Business Combinations.

Property and Equipment

Property and equipment

are recorded at cost, less accumulated depreciation.

Depreciation is calculated using the straight-line method over the related

assets’

estimated, we would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful

further discussion of goodwill and identified intangible assets, refer to Note 5, Business Combinations.

and Equipment

and equipment are recorded at cost, less accumulated depreciation.

Depreciation is calculated using the straight-line method over

the related assets’

estimated useful lives.

Equipment, furniture and fixtures are being amortized over a period of three years.

Expenditures that materially

increase asset life are capitalized, while ordinary maintenance and repairs are expensed as incurred.

Revenue Recognition

Equipment, furniture and fixtures are being amortized over a period of three

that materially increase asset life are capitalized, while ordinary maintenance and repairs are expensed as incurred.

recognize revenue in accordance with Topic 606 to depict the transfer of promised goods or services in an amount that reflects

10 unchanged sentences

or services that are promised to the customer.

Management has identified

the following performance obligations in our contracts with customers:

Data Normalization:

which includes data preparation, product and vendor mapping, product categorization,

data enrichment and other data related services,

Software-as-a-service (“SaaS”):

has identified the following performance obligations in our contracts with customers:

Normalization:

which includes data preparation, product and vendor mapping, product categorization, data enrichment and other

data related services,

Software-as-a-service

(“SaaS”):

which is generated from clients’

access of and

usage of our hosted software solutions on a subscription basis for a specified contract term, which is usually annually.

arrangements, the client cannot take possession of the software during the term of the contract and generally has the right to

access and use the software and receive any software upgrades published during the subscription period,

which includes ongoing data cleansing and normalization, content enrichment, and optimization,

Professional Services:

mainly related to specific customer projects to manage and/or analyze data

and review for cost reduction opportunities.

access of and usage of our hosted software solutions on a subscription

basis for a specified contract term, which is usually annually.

In SaaS arrangements, the client cannot take possession of

the software during the term of the contract and generally has the right to access and use the software and receive any software

upgrades published during the subscription period,

which includes ongoing data cleansing and normalization, content enrichment, and optimization, and

mainly related to specific customer projects to manage and/or analyze data and review for cost reduction opportunities.

contract will typically include Data Normalization, SaaS and Maintenance, which are distinct performance obligations and are accounted

17 unchanged sentences

recognition for our performance obligations are as follows:

Data Normalization and Professional

Our Data Normalization

and Professional Services are typically fixed fee.

When these services are not combined with SaaS or Maintenance revenues as a

single unit of accounting, these revenues are recognized as the services are rendered and when contractual milestones are achieved

and accepted by the customer.

SaaS and Maintenance

revenues are recognized ratably over the contract terms beginning on the commencement date of each contract, which is the date

on which our service is made available to customers.

Normalization and Professional Services

Data Normalization and Professional Services are typically fixed fee.

When these services are not combined with SaaS or Maintenance

revenues as a single unit of accounting, these revenues are recognized as the services are rendered and when contractual milestones

are achieved and accepted by the customer.

and Maintenance

and Maintenance revenues are recognized ratably over the contract terms beginning on the commencement date of each contract, which

is the date on which our service is made available to customers.

do have some contracts that have payment terms that differ from the timing of revenue recognition, which requires us to assess

6 unchanged sentences

good or service to a customer and when the customer pays for that good or service exceeds the one-year threshold.

periods prior to the adoption of ASC 606, we recognized revenues when persuasive evidence of an arrangement existed, delivery had

occurred, the sales price was fixed or determinable, and the collectability of the resulting receivable was reasonably assured.

The adoption of Topic 606 did not result in a cumulative effect adjustment to our opening retained earnings since there was no

significant impact upon adoption of Topic 606.

There was also no material impact to revenues, or any other financial statement

line items for the year ended December 31, 2018 as a result of applying ASC 606.

We have one revenue

stream, from the SaaS business, and have not presented any varying factors that affect the nature, timing and uncertainty of revenues

and cash flows.

of December 31, 2019, we had $1,056,637 of remaining performance obligations recorded as contract liabilities.

of December 31, 2020, we had $2,025,333 of remaining performance obligations recorded as deferred revenue.

We expect to recognize

sales relating to these existing performance obligations of $1,056,637 during the remainder of 2020.

There were no revenues

that were recognized from performance obligations that were partially satisfied prior to January 1, 2018.

Costs to Fulfill

sales relating to these existing performance obligations of during 2021.

to Fulfill a Contract

to fulfill a contract typically include costs related to satisfying performance obligations as well as general and administrative

2 unchanged sentences

with ASC 340-40.

Cost of Revenue

Cost of revenues primarily

represent data center hosting costs, consulting services and maintenance of our large data array that were incurred in delivering

professional services and maintenance of our large data array during the periods presented.

Contract Balances

Contract assets arise

when the revenue associated prior to our unconditional right to receive a payment under a contract with a customer ( i.e .,

unbilled revenue) and are derecognized when either it becomes a receivable or the cash is received.

There were no contract assets

as of December 31, 2019 and 2018 and January 1, 2018.

Contract liabilities

arise when customers remit contractual cash payments in advance of our company satisfying our performance obligations under the

contract and are derecognized when the revenue associated with the contract is recognized when the performance obligation is satisfied.

Contract liabilities were $1,056,637 and $816,714 as of December 31, 2019 and 2018, respectively, and $946,539 as of January 1,

Our company converted

to a corporation from a limited liability company during 2018.

We use the asset and

liability method of accounting for income taxes in accordance with Accounting Standard Codification (“ASC”) Topic 740,

“Income Taxes.”

of revenues primarily represent data center hosting costs, consulting services and maintenance of our large data array that were

incurred in delivering professional services and maintenance of our large data array during the periods presented.

assets arise when the revenue associated prior to our unconditional right to receive a payment under a contract with a customer

( i.e ., unbilled revenue) and are derecognized when either it becomes a receivable or the cash is received.

There were no

contract assets as of December 31, 2020 and 2019.

liabilities arise when customers remit contractual cash payments in advance of our company satisfying our performance obligations

under the contract and are derecognized when the revenue associated with the contract is recognized when the performance obligation

is satisfied.

Deferred revenue for contract liabilities were $2,025,333 and $1,056,637 as of December 31, 2020 and 2019, respectively.

company converted to a corporation from a limited liability company during 2018.

use the asset and liability method of accounting for income taxes in accordance with Accounting Standard Codification (“ASC”)

Topic 740, “Income Taxes.”

Under this method, income tax expense is recognized for the amount of:

(i) taxes payable or refundable

for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized

in an entity’s financial statements or tax returns.

Deferred tax assets and liabilities are measured using enacted tax rates

expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period

that includes the enactment date.

Valuation allowances

are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets

will not be realized.

During the year ended December 31, 2019, we evaluated available evidence and concluded that we may not realize

all the benefits of our deferred tax assets;

therefore, a valuation allowance was established for our deferred tax assets.

ASC Topic 740-10-30

clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes

a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken

or expected to be taken in a tax return.

ASC Topic 740-10-40 provides guidance on derecognition, classification, interest and penalties,

accounting in interim periods, disclosure, and transition.

We have no material uncertain tax positions for any of the reporting

periods presented.

On December 22, 2017,

the Tax Cuts and Jobs Act of 2017, (the “Tax Act”) was enacted.

The Tax Act significantly revised the U.S.

income tax regime by, including but not limited to, lowering the U.S.

corporate income tax rate from 34% to 21% effective January

1, 2018, implementing a territorial tax system, imposing a one-time transition tax on previously untaxed accumulated earnings and

profits of foreign subsidiaries, and creating new taxes on foreign sourced earnings.

During the year ended December 31, 2019, we

completed the accounting for tax effects of the Tax Act under ASC 740.

There were no impacts to the years ended December 31, 2019

Stock-based Compensation Expense

We account for stock-based

(i) taxes payable

or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have

been recognized in an entity’s financial statements or tax returns.

Deferred tax assets and liabilities are measured using

enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered

The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations

in the period that includes the enactment date.

allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred

tax assets will not be realized.

During the year ended December 31, 2020, we evaluated available evidence and concluded that we

may not realize all the benefits of our deferred tax assets;

therefore, a valuation allowance was established for our deferred

Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements

and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a

tax position taken or expected to be taken in a tax return.

ASC Topic 740-10-40 provides guidance on derecognition, classification,

interest and penalties, accounting in interim periods, disclosure, and transition.

We have no material uncertain tax positions

for any of the reporting periods presented.

December 22, 2017, the Tax Cuts and Jobs Act of 2017, (the “Tax Act”) was enacted.

The Tax Act significantly revised

corporate income tax regime by, including but not limited to, lowering the U.S.

corporate income tax rate from 34% to

21% effective January 1, 2018, implementing a territorial tax system, imposing a one-time transition tax on previously untaxed

accumulated earnings and profits of foreign subsidiaries, and creating new taxes on foreign sourced earnings.

During the years

ended December 31, 2020 and 2019, we completed the accounting for tax effects of the Tax Act under ASC 740.

There were no impacts

to the years ended December 31, 2020 and 2019.

Compensation Expense

The Company accounts for stock-based

compensation expense in accordance with the authoritative guidance on share-based payments.

Under the provisions of the guidance,

stock-based compensation expense is measured at the grant date based on the fair value of the option or warrant using a Black-Scholes

option pricing model and is recognized as expense on a straight-line basis over the requisite service period, which is generally

the vesting period.

The fair value of our stock awards for non-employees is estimated based on the fair market value on each vesting

date, accounted for under the variable-accounting method.

The authoritative guidance

also requires that we measure and recognize stock-based compensation expense upon modification of the term of stock award.

stock-based compensation expense for such modification is accounted for as a repurchase of the original award and the issuance

of a new award.

Calculating stock-based

compensation expense requires the input of highly subjective assumptions, including the expected term of the stock-based awards,

stock price volatility, and the pre-vesting option forfeiture rate.

We estimate the expected life of options granted based on historical

exercise patterns, which are believed to be representative of future behavior.

We estimate the volatility of our common stock on

Under the provisions of the guidance, stock-based

compensation expense is measured at the grant date based on the fair value of the option or warrant using a Black-Scholes option pricing

model and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.

The authoritative guidance also requires that the Company measure

and recognize stock-based compensation expense upon modification of the term of stock award.

The stock-based compensation expense for

such modification is accounted for as a repurchase of the original award and the issuance of a new award.

Calculating stock-based compensation

expense requires the input of highly subjective assumptions, including the expected term of the stock-based awards, stock price volatility,

and the pre-vesting option forfeiture rate.

The Company estimates the expected life of options granted based on historical exercise patterns,

which are believed to be representative of future behavior.

The Company estimates the volatility of the Company’s common stock on

the date of grant based on historical volatility.

The assumptions used in calculating the fair value of stock-based awards represent

our best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment.

result, if factors change and we use different assumptions, its stock-based compensation expense could be materially different

The assumptions used in calculating the fair value of stock-based awards represent the

Company’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment.

As a result, if factors change and the Company uses different assumptions, its stock-based compensation expense could be materially different

in the future.

In addition, we are required to estimate the expected forfeiture rate and only recognize expense for those shares

In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares

expected to vest.

We estimate the forfeiture rate based on historical experience of our stock-based awards that are granted, exercised

and cancelled.

The Company estimates the forfeiture rate based on historical experience of its stock-based awards that are granted,

exercised and cancelled.

If the actual forfeiture rate is materially different from the estimate, stock-based compensation expense could

be significantly different from what was recorded in the current period.

We also grant performance based restricted stock awards

The Company also grants performance based restricted stock awards

to employees and consultants.

These awards will vest if certain employee/consultant-specific or company-designated performance

targets are achieved.

If minimum performance thresholds are achieved, each award will convert into a designated number of shares

of our common stock.

These awards will vest if certain employee\consultant-specific or company-designated performance targets

are achieved.

If minimum performance thresholds are achieved, each award will convert into a designated number of the Company’s

common stock.

If minimum performance thresholds are not achieved, then no shares will be issued.

Based upon the expected

levels of achievement, stock-based compensation is recognized on a straight-line basis over the requisite service period.

levels of achievement are reassessed over the requisite service periods and, to the extent that the expected levels of achievement

change, stock-based compensation is adjusted in the period of change and recorded on the statements of operations and the remaining

unrecognized stock-based compensation is recorded over the remaining requisite service period.

Based upon the expected levels of achievement,

stock-based compensation is recognized on a straight-line basis over the requisite service period.

The expected levels of achievement

are reassessed over the requisite service periods and, to the extent that the expected levels of achievement change, stock-based compensation

is adjusted in the period of change and recorded on the statements of operations and the remaining unrecognized stock-based compensation

is recorded over the remaining requisite service period.

Refer to Note 9, Stockholders’

Equity, for additional detail.

Loss Per Share

We compute earnings

(loss) per share in accordance with ASC 260, “Earnings per Share”

which requires presentation of both basic and diluted

earnings (loss) per share (“EPS”) on the face of the income statement.

Basic EPS is computed by dividing the loss available

to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period.

EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible

preferred stock using the if-converted method.

In computing diluted EPS, the average stock price for the period is used in determining

the number of shares assumed to be purchased from the exercise of stock options or warrants.

Diluted EPS excludes all dilutive

potential shares if their effect is anti-dilutive.

As of December 31, 2019 and 2018, we had 1,650,511 and 371,848, respectively,

common stock equivalents outstanding.

compute earnings (loss) per share in accordance with ASC 260, “Earnings per Share”

which requires presentation of

both basic and diluted earnings (loss) per share (“EPS”) on the face of the income statement.

Basic EPS is computed

by dividing the loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator)

during the period.

Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury

stock method and convertible preferred stock using the if-converted method.

In computing diluted EPS, the average stock price

for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.

Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.

As of December 31, 2020 and 2019, we had

790,847 and 1,650,511, respectively, common stock equivalents outstanding.

Indemnification

We provide indemnification

of varying scope to certain customers against claims of intellectual property infringement made by third parties arising from the

use of our software.

In accordance with authoritative guidance for accounting for guarantees, we evaluate estimated losses for

such indemnification.

We consider such factors as the degree of probability of an unfavorable outcome and the ability to make a

reasonable estimate of the amount of loss.

To date, no such claims have been filed against our company and no liability has been

recorded in our financial statements.

As permitted under Delaware

law, we have agreements whereby we indemnify our officers and directors for certain events or occurrences while the officer or

director is, or was, serving at our company’s request in such capacity.

The maximum potential amount of future payments we

could be required to make under these indemnification agreements is unlimited.

In addition, we have directors’

provide indemnification of varying scope to certain customers against claims of intellectual property infringement made by third

parties arising from the use of our software.

In accordance with authoritative guidance for accounting for guarantees, we evaluate

estimated losses for such indemnification.

We consider such factors as the degree of probability of an unfavorable outcome and

the ability to make a reasonable estimate of the amount of loss.

To date, no such claims have been filed against our company and

no liability has been recorded in our financial statements.

permitted under Delaware law, we have agreements whereby we indemnify our officers and directors for certain events or occurrences

while the officer or director is, or was, serving at our company’s request in such capacity.

The maximum potential amount

of future payments we could be required to make under these indemnification agreements is unlimited.

In addition, we have

directors’

and officers’

liability insurance coverage that is intended to reduce our financial exposure and may enable us to recover any payments above

the applicable policy retention, should they occur.

In connection with the Class

Action claims and investigations described in Item 3.

Legal Proceedings of this Annual Report on 10-K, we are obligated to indemnify

our officers and directors for costs incurred in defending against these claims and investigations.

Because we currently do not

have the resources to pay for these costs, our directors and officers liability insurance carrier has agreed to indemnify these

persons even though the $750,000 retention under such policy has not yet been met.

Ultimately, we will be obligated to pay the

amount of the retention to the extent of actual settlement and defense costs, which payments could have a material adverse effect

on the Company.

liability insurance coverage that is intended to reduce our financial exposure and may enable

us to recover any payments above the applicable policy retention, should they occur.

connection with the Class Action claims and investigations described in Item 3.

Legal Proceedings of this Annual Report on Form 10-K,

the Company is obligated to indemnify its officers and directors for costs incurred in defending against these claims and investigations.

Contingencies

From time to time,

we may be involved in legal and administrative proceedings and claims of various types.

We record a liability in our consolidated

financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated.

Management reviews these estimates in each accounting period as additional information becomes known and adjusts the loss provision

when appropriate.

If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated

financial statements.

If a loss is probable but the amount of loss cannot be reasonably estimated, we disclose the loss contingency

and an estimate of possible loss or range of loss (unless such an estimate cannot be made).

We do not recognize gain contingencies

until they are realized.

time to time, we may be involved in legal and administrative proceedings and claims of various types.

We record a liability in

our consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably

Management reviews these estimates in each accounting period as additional information becomes known and adjusts the

loss provision when appropriate.

If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in

the consolidated financial statements.

If a loss is probable but the amount of loss cannot be reasonably estimated, we disclose

the loss contingency and an estimate of possible loss or range of loss (unless such an estimate cannot be made).

We do not recognize

gain contingencies until they are realized.

Legal costs incurred in connection with loss contingencies are expensed as incurred.

Refer to Note 9,

Commitments and Contingencies, for further information.

Use of Estimates

The preparation of consolidated

financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported

and disclosed in the consolidated financial statements and accompanying notes.

The Company regularly evaluates estimates and assumptions

related to allowance for doubtful accounts, the estimated useful lives and recoverability of long-lived assets, equity component

of convertible debt, stock-based compensation, and deferred income tax asset valuation allowances.

The Company bases its estimates

and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances,

the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of

costs and expenses that are not readily apparent from other sources.

The actual results experienced by the Company may differ materially

and adversely from the Company’s estimates.

To the extent there are material differences between the estimates and the actual

results, future results of operations will be affected.

Recently Issued Accounting Pronouncements

In February 2016, the

Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No.

2016-02, Leases

(Topic 842) (“ASU 2016-02”).

ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease

liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer

than 12 months, as well as the disclosure of key information about leasing arrangements.

Disclosures are required to provide the

amount, timing and uncertainty of cash flows arising from leases.

A modified retrospective transition approach is provided for

lessees of leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial

statements, with certain practical expedients available.

ASU 2016-02 is effective for fiscal years beginning after December 15,

2018, including interim periods within those fiscal years, with early adoption permitted.

In July 2018, the FASB issued ASU No.

Refer to Note 8, Commitments and Contingencies, for further information.

preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions

that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes.

The Company regularly

evaluates estimates and assumptions related to allowance for doubtful accounts, the estimated useful lives and recoverability

of long-lived assets, equity component of convertible debt, stock-based compensation, and deferred income tax asset valuation

The Company bases its estimates and assumptions on current facts, historical experience and various other factors

that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the

carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.

The actual results experienced by the Company may differ materially and adversely from the Company’s estimates.

To the extent

there are material differences between the estimates and the actual results, future results of operations will be affected.

Issued Accounting Pronouncements

February 2016, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”)

2016-02, Leases (Topic 842) (“ASU 2016-02”).

ASU 2016-02 requires a lessee to record a right-of-use asset

and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all

leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements.

are required to provide the amount, timing and uncertainty of cash flows arising from leases.

A modified retrospective transition

approach is provided for lessees of leases existing at, or entered into after, the beginning of the earliest comparative period

presented in the financial statements, with certain practical expedients available.

ASU 2016-02 is effective for fiscal years

beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted.

2018, the FASB issued ASU No.

2018-11, Leases (Topic 842) Targeted Improvements (“ASU 2018-11”).

ASU 2018-11 allows all entities adopting

ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new

leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings

in the period of adoption.

ASU 2018-11 also allows lessors to not separate non-lease components from the associated lease component

if certain conditions are met.

We adopted the provisions of ASU 2016-02 and ASU 2018-11 in the quarter beginning January 1, 2019.

The adoption resulted in the recognition of additional disclosures and a right of use asset of approximately $53,000 included as

a component of prepaid expenses and other assets and a lease liability of approximately $53,000, which is included as a component

of accounts payable and accrued liabilities.

In October 2018, the

FASB issued ASU No.

allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an

entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening

balance of retained earnings in the period of adoption.

ASU 2018-11 also allows lessors to not separate non-lease components from

the associated lease component if certain conditions are met.

We adopted the provisions of ASU 2016-02 and ASU 2018-11 in the

quarter beginning January 1, 2019.

The adoption resulted in the recognition of additional disclosures and a right of use asset

of approximately $53,000 included as a component of prepaid expenses and other assets and a lease liability of approximately $53,000,

which is included as a component of accounts payable and accrued liabilities at December 31, 2019.

The Company did not have any

right of use assets or lease liabilities at December 31, 2020.

October 2018, the FASB issued ASU No.

2018-17, Consolidation (Topic 810):

Targeted Improvements to Related Party Guidance for Variable

Interest Entities (“ASU 2018-17”).

ASU 2018-17 provides that indirect interests held through related parties

in common control arrangements should be considered on a proportional basis for determining whether fees paid to decision makers

and service providers are variable interests.

ASU 2018-17 is effective for annual and interim periods beginning after December

15, 2019, with early adoption permitted.

We adopted this new standard in the first quarter of fiscal 2020, and the adoption of

the standard did not have a material impact on our consolidated financial statements.

Targeted Improvements to Related Party

Guidance for Variable Interest Entities (“ASU 2018-17”).

ASU 2018-17 provides that indirect interests held

through related parties in common control arrangements should be considered on a proportional basis for determining whether fees

paid to decision makers and service providers are variable interests.

ASU 2018-17 is effective for annual and interim periods

beginning after December 15, 2019, with early adoption permitted.

We adopted this new standard in the first quarter of fiscal

2020, and the adoption of the standard did not have a material impact on our consolidated financial statements.

August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820):

Disclosure Framework—Changes

to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements

on fair value measurements.

ASU 2018-13 is effective in the first quarter of fiscal 2020, and earlier adoption is permitted.

We adopted this new standard in the first quarter of fiscal 2020, and the adoption of the standard did not have a material impact

on our consolidated financial statements.

In January 2017, the

FASB issued ASU No.

to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure

requirements on fair value measurements.

ASU 2018-13 is effective in the first quarter of fiscal 2020, and earlier adoption is

We adopted this new standard in the first quarter of fiscal 2020, and the adoption of the standard did not have a material

impact on our consolidated financial statements.

January 2017, the FASB issued ASU No.

2017-04, Intangibles - Goodwill and Other (Topic 350):

Simplifying the Test for Goodwill Impairment

(“ASU 2017-04”), which eliminates step two from the goodwill impairment test.

Under ASU 2017-04, an entity should recognize

an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair value up to the amount of

goodwill allocated to that reporting unit.

We adopted this new standard in the first quarter of fiscal 2020, and the adoption of

the standard did not have a material impact on our consolidated financial statements.

In June 2018, the FASB

issued ASU No.

Simplifying the Test for Goodwill

Impairment (“ASU 2017-04”), which eliminates step two from the goodwill impairment test.

Under ASU 2017-04, an

entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds its fair

value up to the amount of goodwill allocated to that reporting unit.

We adopted this new standard in the first quarter of fiscal

2020, and the adoption of the standard did not have a material impact on our consolidated financial statements.

June 2018, the FASB issued ASU No.

2018-07, Stock-based Compensation:

Improvements to Nonemployee Share-based Payment Accounting, which

amends the existing accounting standards for share-based payments to nonemployees.

This ASU aligns much of the guidance on measuring

and classifying nonemployee awards with that of awards to employees.

Under the new guidance, the measurement of nonemployee equity

awards is fixed on the grant date.

The effective date for the standard is for interim periods in fiscal years beginning after December

15, 2018, with early adoption permitted, but no earlier than our adoption date of Topic 606.

The new guidance is required to be

applied retrospectively with the cumulative effect recognized at the date of initial application.

We adopted this new standard

in the first quarter of fiscal 2019, and the adoption of the standard did not have a material impact on our consolidated financial

In June 2016, the FASB

issued ASU No.

Improvements to Nonemployee Share-based Payment

Accounting, which amends the existing accounting standards for share-based payments to nonemployees.

This ASU aligns much

of the guidance on measuring and classifying nonemployee awards with that of awards to employees.

Under the new guidance, the

measurement of nonemployee equity awards is fixed on the grant date.

The effective date for the standard is for interim periods

in fiscal years beginning after December 15, 2018, with early adoption permitted, but no earlier than our adoption date of Topic

The new guidance is required to be applied retrospectively with the cumulative effect recognized at the date of initial application.

We adopted this new standard in the first quarter of fiscal 2019, and the adoption of the standard did not have a material impact

on our consolidated financial statements.

June 2016, the FASB issued ASU No.

2016-13 (“ASU 2016-13”) “Financial Instruments - Credit Losses”

(“ASC 326”):

Measurement of Credit Losses on Financial Instruments”

which requires the measurement and recognition of expected credit

losses for financial assets held at amortized cost.

ASU 2016-13 replaces the existing incurred loss impairment model with an expected

loss model which requires the use of forward-looking information to calculate credit loss estimates.

It also eliminates the concept

of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through

an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities.

These changes will result

in earlier recognition of credit losses.

In November 2019, the FASB issued ASU 2019-10 “Financial Instruments –

Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)”

(“ASC 2019-10”), which defers

the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022, including interim periods within those fiscal

years, for public entities which meet the definition of a smaller reporting company.

The Company will adopt ASU 2016-13 effective

January 1, 2023.

Management is currently evaluating the effect of the adoption of ASU 2016-13 on the consolidated financial statements.

The effect will largely depend on the composition and credit quality of our investment portfolio and the economic conditions at

the time of adoption.

Results of Operations

The COVID-19 Pandemic has disrupted our business and the

business of our hospital customers.

Our operations and

business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout

the United States and the world.

The New York and New Jersey area, where the Company is headquartered, is currently at one of

the epicenters of the coronavirus outbreak in the United States.

The Company has been following the recommendations of local health

authorities to minimize exposure risk for its team members since the outbreak.

In addition, the Company’s

customers (hospitals) have also experienced extraordinary disruptions to their businesses and supply chains, while experiencing

unprecedented demand for health care services related to COVID-19.

As a result of these extraordinary disruptions to our customers’

business, our customers are currently focused on meeting the nation’s health care needs in response to the COVID-19 pandemic.

As a result, there is a significant risk that our customers will not be able to focus any resources on expanding the utilization

of our services, which could adversely impact our future growth prospects, at least until the adverse effects of the pandemic

In addition, the financial impact of COVID-19 on our hospital customers could cause the hospital to delay payments due

to us for services, which could negatively impact our cash flows.

We are endeavoring

to mitigate these risks through the sale of personal protective equipment (“PPE”) and COVID-19 rapid test kits to

the health care industry, including many of our hospital customers.

The sale of PPE and rapid test kits for COVID-19 represent

a new business for the Company and is subject to the myriad risks associated with any new venture.

The Company has for example

encountered great difficulty in attempting to secure reliable sources of supply for both COVID-19 Rapid Test Kits and PPE including,

3M N95 masks, which are the preferred medical grade mask of US healthcare companies.

Further, the Company has encountered shipping

delays with regard to masks and other PPE, and significant quality related issues regarding N95 masks.

In addition, regarding

its sourcing of COVID-19 Rapid Test Kits, the Company has encountered significant shipping delays, as well as reduced quantities.

Consequently, there is no assurance as to the timing or quantities of any future deliveries of COVID-19 Test Kits.

has yet to complete the sale of any COVID-19 rapid test kits and had no test kits or PPE in inventory as of December 31, 2019

and had 19,000 test kit units as of the date of this report.

In addition, changes in FDA processes governing the sale of COVID-19

serology tests could have the effect of rendering the COVID-19 serology tests to be sold by the Company not saleable in the United

States, which could have a material adverse effect on the Company.

See Government Regulation.

There can be no assurance that the

Company will be able to generate any significant revenue from the sale of PPE products or rapid test kits.

The Company has yet to complete the sale of any COVID-19 rapid test

Through the date of filing we have not generated any material revenue from the sale of PPE.

Year Ended December 31, 2019 Compared

to Year Ended December 31, 2018

The following summary

of our results of operations should be read in conjunction with our consolidated financial statements for the years ended December

31, 2019 and 2018.

Our operating results

for the years ended December 31, 2019 and 2018 are summarized as follows:

Statement of Operations Data:

Operating expenses

Loss from operations

(11,897,491 )

Total other income (expense)

(11,312,500 )

Net loss per share, basic and diluted

Weighted average shares outstanding, basic and diluted

Our significant balance sheet accounts as of December 31, 2019

and 2018 are summarized as follows:

which requires the measurement and recognition of expected

credit losses for financial assets held at amortized cost.

ASU 2016-13 replaces the existing incurred loss impairment model with

an expected loss model which requires the use of forward-looking information to calculate credit loss estimates.

It also eliminates

the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be

recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities.

changes will result in earlier recognition of credit losses.

In November 2019, the FASB issued ASU 2019-10 “Financial Instruments

Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)”

(“ASC 2019-10”),

which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022, including interim periods within

those fiscal years, for public entities which meet the definition of a smaller reporting company.

The Company will adopt ASU 2016-13

effective January 1, 2023.

Management is currently evaluating the effect of the adoption of ASU 2016-13 on the consolidated financial

The effect will largely depend on the composition and credit quality of our investment portfolio and the economic

conditions at the time of adoption.

of Operations

COVID-19 Pandemic has disrupted our business and the business of our hospital customers.

operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic which

spread throughout the United States and the world.

The New York and New Jersey area, where the Company is headquartered, was at

one of the epicenters of the coronavirus outbreak in the United States.

The Company has followed the recommendations of local

health authorities to minimize exposure risk for its team members since the outbreak.

addition, the Company’s customers (hospitals) have also experienced extraordinary disruptions to their businesses and supply

chains, while experiencing unprecedented demand for health care services related to COVID-19.

As a result of these extraordinary

disruptions to our customers’

business, our customers have been focused on meeting the nation’s health care needs

in response to the COVID-19 pandemic.

As a result, there is a significant risk that our customers will not be able to focus any

resources on expanding the utilization of our services, which could adversely impact our future growth prospects, at least until

the adverse effects of the pandemic subside.

In addition, the financial impact of COVID-19 on our hospital customers could cause

the hospital to delay payments due to us for services, which could negatively impact our cash flows.

have attempted to mitigate these risks through the sale of personal protective equipment (“PPE”) and COVID-19 rapid

test kits to the health care industry, including many of our hospital customers.

sale of PPE and rapid test kits for COVID-19 represented a new business for the Company and is subject to the myriad risks associated

with any new venture.

The Company encountered great difficulty in attempting to secure reliable sources of supply for both COVID-19

Rapid Test Kits and PPE.

The Company currently has no contracted supply of Rapid Test Kits or PPE.

During the year ended December

31, 2020, the Company has completed only minimal sales of COVID-19 rapid test kits and PPE.

In addition, changes in market conditions

and FDA processes governing the sale of COVID-19 serology tests could have the effect of rendering the COVID-19 serology tests

held by the Company not saleable in the United States, which could have a material adverse effect on the Company’s financial

condition and results of operations.

There can be no assurance that the Company will be able to generate any significant revenue

from the sale of PPE products or rapid test kits, and as of the date of this report, the Company has not generated any material

revenue from the sale of PPE or rapid test kits.

Company is no longer actively seeking to procure and sell Test Kits or PPE.

Instead, the Company is focused on selling its

current inventory of PPE and Test Kits.

The Company may receive commissions for acting as an intermediary with respect to the

sale of PPE and/or Test Kits.

However, there is no assurance the Company will realize any material revenue from these activities.

Ended December 31, 2020 Compared to Year Ended December 31, 2019

following summary of our results of operations should be read in conjunction with our consolidated financial statements for the

years ended December 31, 2020 and 2019.

operating results for the years ended December 31, 2020 and 2019 are summarized as follows:

Cost of revenues

General and administrative

Other (expense) income

Provision for income taxes

significant balance sheet accounts as of December 31, 2020 and 2019 are summarized as follows:

Balance Sheet Data:

Accounts receivable, net

Prepaid expenses and other current assets

Total current assets

4 unchanged sentences

Stockholders’

equity/(deficit)

Revenue for the year

ended December 31, 2019 was $5,548,119, compared to revenue for the year ended December 31, 2018, which was $3,421,937.

in revenue is primarily related to revenue from the addition of new multi-year customer contracts during 2019, data consulting

projects completed during 2019, license renewals in 2019, and monthly maintenance revenue from new customers in the last half of

Given the disruption caused to our hospital customers by the COVID-19 pandemic, we expect our near term revenues to be adversely

Customer retention includes monthly and annual recurring revenue that should not be significantly impacted by the pandemic.

General and administrative expenses increased $12,404,731 to

for the year ended December 31, 2020 was $5,213,118, compared to revenue for the year ended December 31, 2018, which was $5,548,119.

The decline in revenue is primarily related to decreases in one time revenue from the addition in 2019 of new multi-year customer

contracts and a decrease in revenue from data consulting projects which were completed during 2019.

Given the disruption caused

to our hospital customers by the COVID-19 pandemic, we expect that our near-term revenues will likely be adversely impacted.

General and administrative expenses decreased $5,320,677 to $7,742,850

for the year ended December 31, 2020, as compared to $13,063,527 in the same period of 2019.

Salary and wages increased

approximately $1.7 million due to our hiring of personnel in 2019 and having no employees in 2018.

Insurance increased by approximately

$156,000 due to an increase in Directors and Officers insurance and other insurance coverages.

Travel increased by approximately

$279,000 mainly related to sales opportunities.

We expect travel expenses to decrease significantly in 2020.

Bad debt expense increased

to $344,412 in 2019 from $0 in 2018.

Accounting and legal expenses increased approximately $1.6 million due to the regulatory filings

required and the acquisition completed on February 1, 2019 and the listing of the Company’s stock on the Nasdaq Stock Market.

We also expect legal and accounting fees to decrease in 2020.

Stock-based compensation expense increased $7,482,254 related to

equity awards to employees, directors, and consultants and the transfer of common shares by our CEO and a former significant shareholder

to non-employee consultants.

SEC related expenses increased approximately $287,000.

We expect stock-based compensation to be significant

in 2020 due to equity awards made to officers, directors, employees and consultants in April 2020.

We had other income of $584,991 in 2019 compared to other expense

of $229,424 in 2018.

In 2019, there was a gain on the fair value of convertible note receivable of $372,282 compared to a loss

on fair value of asset of $112,944 in 2018.

This decrease is largely due to decreases

of approximately $3.8 million in non-cash stock compensation, approximately $900,000 in salary expense, approximately $415,000 in travel

expense, approximately $775,000 in accounting and auditing expense, and approximately $930,000 in research and development costs, partially

offset by an increase of approximately $973,000 in legal fees largely related to the matters described in Item 3.

Legal Proceedings in

had other expense of $1,357,339 in 2020 compared to other income of $584,991 in 2019.

In 2020, other expenses were related to

losses on stock settlement of payables.

In 2019, there was a gain on the fair value of convertible note receivable of $372,282

and a gain on the fair value of asset (warrant) in 2019 of $55,000.

Interest expense decreased from $23,720 in 2019 to $0 in 2020.

was a result of the conversion of the debt to equity in 2019.

The Company had a gain on the fair value of asset (warrant)

in 2019 of $55,000 compared to a loss of $66,000 in 2018.

On December 22, 2017,

the Tax Cuts and Jobs Act of 2017, (the “Tax Act”) was enacted.

The Tax Act significantly revised the U.S.

income tax regime by, including but not limited to, lowering the U.S.

corporate income tax rate from 34% to 21% effective January

1, 2018, implementing a territorial tax system, imposing a one-time transition tax on previously untaxed accumulated earnings and

profits of foreign subsidiaries, and creating new taxes on foreign sourced earnings.

As of December 31, 2018, the Company completed

the accounting for tax effects of the Tax Act under ASC 740.

Liquidity and Capital

Going Concern

The following discussion

of SCWorx’s Liquidity and Capital Resources with regard to sources and uses of cash in 2019 is not indicative of the future

sources and uses of cash by the combined Company after giving effect to the acquisition of SCWorx, which occurred on February

Management has concluded and our auditors have indicated in their report on our consolidated financial statements for

the year ended December 31, 2019 that conditions exist that raise substantial doubt about our ability to continue as a going concern

since we may not have sufficient capital resources from operations and existing financing arrangements to meet our operating expenses

and working capital requirements.

As of December 31, 2019, we had a working capital deficit of $1,768,834 and accumulated deficit

of $12,794,473.

During the year ended December 31, 2019, we had a net loss of $11,312,500 and used $4,691,290 of cash in operations.

We have historically incurred operating losses and may continue to incur operating losses for the foreseeable future.

that these conditions raise substantial doubt about our ability to continue as a going concern.

This may hinder our future ability

to obtain financing or may force us to obtain financing on less favorable terms than would otherwise be available.

If we are unable

to develop sufficient revenues and additional customers for our products and services, we may not generate enough revenue to sustain

our business, and we may fail, in which case our stockholders would suffer a total loss of their investment.

There can be no assurance

that we will be able to continue as a going concern.

As of June 3, 2020, we

had only limited cash on hand, and we are experiencing negative cash flows from operations.

Consequently, we need to raise additional

capital in the near term to fund our operations and the implementation of our business plan.

On May 5, 2020, we received $293,972 in financing from the US

government’s Payroll Protection Program (“PPP”).

and Capital Resources

Management has concluded and

our auditors have indicated in their report on our consolidated financial statements for the year ended December 31, 2020 that conditions

exist that raise substantial doubt about our ability to continue as a going concern since we may not have sufficient capital resources

from operations and existing financing arrangements to meet our operating expenses and working capital requirements.

As of December 31,

2020, we had a working capital deficit of $2,414,635 and accumulated deficit of $20,196,823.

During the year ended December 31, 2020,

we had a net loss of $7,402,350 and used $959,070 of cash in operations.

We have historically incurred operating losses and may continue

to incur operating losses for the foreseeable future.

We believe that these conditions raise substantial doubt about our ability to continue

as a going concern.

This may hinder our future ability to obtain financing or may force us to obtain financing on less favorable terms

than would otherwise be available.

If we are unable to develop sufficient revenues and additional customers for our products and services,

we may not generate enough revenue to sustain our business, and we may fail, in which case our stockholders would suffer a total loss

of their investment.

There can be no assurance that we will be able to continue as a going concern.

May 5, 2020, we obtained a $293,972 unsecured loan payable through the Paycheck Protection Program (“PPP”), which

was enacted as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES ACT”).

The funds were received

from Bank of America through a loan agreement pursuant to the CARES Act.

The CARES Act was established in order to enable small

businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses

for up to 2.5 times their average monthly payroll costs.

The amount borrowed under the CARES Act and used for payroll costs, rent,

mortgage interest, and utility costs during the 24 week period after the date of loan disbursement is eligible to be forgiven

provided that (a) we use the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used

to cover payroll costs (including benefits), rent, mortgage interest, and utility costs.

While the full loan amount may be forgiven,

the amount of loan forgiveness will be reduced if, among other reasons, we do not maintain staffing or payroll levels or less

than 60% of the loan proceeds are used for payroll costs.

Principal and interest payments on any unforgiven portion of the PPP

Funds (the “PPP Loan”) will be deferred to the date the SBA remits the borrower’s loan forgiveness amount to

the lender or, if the borrower does not apply for loan forgiveness, 10 months after the end of the borrower’s loan forgiveness

period for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date.

prepayment penalty on the CARES Act Loan.

March 17, 2021, we received an additional $139,595 in financing from the US government’s Payroll Protection Program (“PPP”).

We entered into a loan agreement with Bank of America.

loan agreement was pursuant to the CARES Act.

The CARES Act was established in order to enable small businesses to pay employees

during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their

average monthly payroll costs.

The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company

uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs

(including benefits), rent, mortgage interest, and utility costs.

The amount of loan forgiveness will be reduced if, among other

reasons, the Company does not maintain staffing or payroll levels.

Principal and interest payments on any unforgiven portion of

the PPP Funds (the “PPP Loan”) will be deferred for six months and will accrue interest at a fixed annual rate of 1.0%

and carry a two year maturity date.

There is no prepayment penalty on the CARES Act Loan.

During May 2020, we

received $515,000 of a committed $565,000 from the sale of 135,527 shares of common stock (at a price of $3.80 per share) and

warrants to purchase 169,409 shares of common stock, at an exercise price of $4.00 per share.

This transaction is subject to execution

of definitive documents.

This loan agreement was pursuant to the CARES Act.

The CARES Act was established

in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans

to qualifying businesses for up to 2.5 times their average monthly payroll costs.

The amount borrowed under the CARES Act is eligible

to be forgiven provided that (a) the Company uses the PPP Funds during the six month period after receipt thereof, and (b) the

PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs.

The amount of

loan forgiveness will be reduced if, among other reasons, the Company does not maintain staffing or payroll levels.

and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred for six months

and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date.

There is no prepayment penalty on

the CARES Act Loan.

May 2020, we received $515,000 from the sale of 135,527 shares of common stock (at a price of $3.80 per share) and warrants to

purchase 169,409 shares of common stock, at an exercise price of $4.00 per share.

Of the $515,000 investment, $125,000 is subject

to execution of definitive documents.

We are currently experiencing

an increasing working capital deficiency.

As of December 31, 2019, we had a working capital deficit of approximately $1.8 million,

compared to a deficit of $49,655 as of December 31, 2018.

The approximate $1.7 million increase in our working capital deficit

was due primarily to an approximate $1.6 million increase in accounts payable, a $240,000 increase in contract liabilities, due

to the selling additional annual contracts to customers, and an approximate $1 million decrease in acquisition related convertible

notes and interest receivable, which were converted to equity in 2019, partially offset by approximately $623,000 increase in accounts

receivable, due to the additional revenue in 2019 and approximately $411,000 increase in cash.

Based on our current business

plan, we anticipate that our operating activities will use approximately $250,000 in cash per month over the next twelve months,

or approximately $3.0 million.

Currently we have limited cash on hand, and consequently, we are unable to fully implement our current

business plan.

a working capital deficiency.

As of December 31, 2020, we had a working capital deficit of approximately $2.4 million, compared to a deficit

of approximately $1.8 million as of December 31, 2019.

The approximate $645,000 increase in our working capital deficit was due primarily

to an approximate $969,000 increase in contract liabilities, due to the selling additional annual contracts to customers, an approximate

$375,000 increase in equity financing not yet converted, an approximate $188,000 increase in accounts payable and accrued expenses, an

approximate $112,000 decrease in cash, and an approximate $77,000 decrease in accounts receivable, partially offset by an approximate

$998,000 increase in inventory and an approximate $76,000 increase in prepaid expenses.

As of May 15, 2021, we had only limited cash on hand, and we are experiencing

negative cash flows from operations.

Consequently, we need to raise additional capital as soon as possible to fund our operations and

the implementation of our business plan.

on our current business plan, we anticipate that our operating activities will use approximately $400,000 in cash per month over

the next twelve months, or approximately $4.8 million.

Currently we have limited cash on hand, and consequently, we are unable

to implement our current business plan.

Accordingly, we have an immediate need for additional capital to fund our operating activities.

In order to remedy

this liquidity deficiency, we are actively seeking to raise additional funds through the sale of equity and debt securities, and

ultimately, we will need to generate substantial positive operating cash flows.

Our internal sources of funds will consist of

cash flows from operations, but not until we begin to realize additional revenues from the sale of our products and services.

As previously stated, our operations are generating negative cash flows, and thus adversely affecting our liquidity.

able to secure sufficient funding in the near term to fully implement our business plan, we expect that our operations could begin

to generate significant cash flows during early 2021, which should ameliorate our liquidity deficiency.

If we are unable to raise

additional funds in the near term, we will not be able to fully implement our business plan, in which case there could be a material

adverse effect on our results of operations and financial condition.

In the event we do

not generate sufficient funds from revenues or financing through the issuance of common stock or from debt financing, we may be

unable to fully implement our business plan and pay our obligations as they become due, any of which circumstances would have a

material adverse effect on our business prospects, financial condition, and results of operations.

The accompanying financial statements

do not include any adjustments that might be required should the Company be unable to recover the value of its assets or satisfy

its liabilities (see Note 2 to the Financial Statements - Liquidity/Going Concern).

Based on our limited

availability of funds we expect to spend minimal amounts on software development and capital expenditures.

We expect to fund any

software development expenditures through a combination of cash flows from operations and proceeds from equity and/or debt financing.

If we are unable to generate positive cash flows from operations, and/or raise additional funds (either through debt or equity),

we will be unable to fund our software development expenditures, in which case, there could be an adverse effect on our business

and results of operations.

Year Ended December 31,

Net cash used in operating activities

In order to remedy this liquidity deficiency, we have cut spending

and are actively seeking to raise additional funds through the sale of equity and debt securities, and ultimately, we will need to generate

substantial positive operating cash flows.

Our internal sources of funds will consist of cash flows from operations, but not until we

begin to realize additional revenues from the sale of our products and services.

As previously stated, our operations are generating negative

cash flows, and thus adversely affecting our liquidity.

If we are able to secure sufficient funding in the second quarter of 2021 to fully

implement our business plan, we expect that our operations could begin to generate significant cash flows in the first quarter of 2022,

which should ameliorate our liquidity deficiency.

If we are unable to raise additional funds in the near term, we will not be able to

fully implement our business plan, in which case there could be a material adverse effect on our results of operations and financial condition.

the event we do not generate sufficient funds from revenues or financing through the issuance of common stock or from debt financing,

we will be unable to fully implement our business plan and pay our obligations as they become due, any of which circumstances

would have a material adverse effect on our business prospects, financial condition, and results of operations.

The accompanying

financial statements do not include any adjustments that might be required should the Company be unable to recover the value of

its assets or satisfy its liabilities (see Note 2 to the Financial Statements - Liquidity/Going Concern).

on our current limited availability of funds, we expect to spend minimal amounts on software development and capital expenditures.

We expect to fund any software development expenditures through a combination of cash flows from operations and proceeds from

equity and/or debt financing.

If we are unable to generate positive cash flows from operations, and/or raise additional funds

(either through debt or equity), we will be unable to fund our software development expenditures, in which case, there could be

an adverse effect on our business and results of operations.

ended December 31,

cash used in operating activities

$ (4,691,290 )

Net cash provided by (used in) investing activities

Net cash provided by financing activities

Net increase in cash

Our operations through

December 31, 2019 have resulted in negative cash flows from operations of $4,691,290.

If we are able to generate additional revenue

through the addition of new customers, combined with an anticipated reduction in legal and accounting expenses, we believe we

may begin to generate positive operating cash flows in early 2021.

However, there is no assurance we will be able to increase

our revenue sufficiently so as to generate positive operating cash flows within this time frame.

Operating Activities

Net cash used in operating

activities was $4,691,290 for the year ended December 31, 2019, mainly related to the net loss of $11,312,500, and offset by non-cash

stock-based compensation of $7,482,254 related to various equity awards to employees and non-employees.

Net cash used in operating

activities from operations was $241,080 for the year ended December 31, 2018, mainly related to the net loss of $380,603, increase

in accounts receivable of $173,200, amortization of note discount of $48,261, non-cash expenses relating to the fair value of convertible

notes and warrants of $178,944, a decrease in deferred revenue of $129,825 and an increase in accounts payable and accrued expenses

Investing Activities

Net cash provided by investing

activities was $4,915,236 for the year ended December 31, 2019, related to the cash acquired in the reverse acquisition of $5,441,437,

partially offset by advances to a shareholder of $199,549 and the purchase of Alliance convertible notes receivable of $215,000

and capital expenditures of $111,652.

Net cash used in investing

activities was $1,703,466 for the year ended December 31, 2018, which were primarily a $1,035,000 loan to Alliance and $547,116

of advances to a shareholder.

We expect cash used

in investing activities to decrease during 2020.

Financing Activities

Net cash provided by

financing activities was $187,548 for the year ended December 31, 2019, primarily related to the proceeds from a note payable,

related party.

Cash provided by financing

activities was $2,005,846 for the year ended December 31, 2018, primarily related to $1,250,000 of proceeds from the sale of common

stock and $755,846 of borrowings from a related party.

Contractual Cash Obligations

Refer to Note 9, Commitments

and Contingencies, in the accompanying consolidated financial statements for additional detail.

Off-Balance Sheet Arrangements

As of December 31,

2019, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

Quantitative and Qualitative

Disclosures About Market Risk

We are a smaller reporting

company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

Financial Statements and Supplementary

The consolidated financial

statements are included in Part IV, Item 15 (a) (1) of this Report.

Changes in and Disagreements with Accountants on

Accounting and Financial Disclosure

cash provided by investing activities

cash provided by financing activities

Our operations through December 31, 2020 have resulted in negative

cash flows from operations of $959,070.

If we are able to raise additional capital during the second quarter of 2021 and generate additional

revenue through the acquisition of new customers, coupled with an anticipated reduction in legal and accounting expenses, we believe we

may begin to generate positive operating cash flows during the first quarter of 2022.

However, there is no assurance we will be able to

increase our revenue sufficiently so as to generate positive operating cash flows within this time frame.

Net cash used in operating activities was $959,070 for the year ended

December 31, 2020, mainly related to the net loss of $7,402,350, and offset by non-cash stock-based compensation of $3,284,570 related

to various equity awards to employees and non-employees, $1,612,538 in non-cash losses related to the settlement of accounts payable,

a $848,473 increase in accounts payable and accrued liabilities, and a $968,696 increase in deferred revenue, partially offset by a $76,470

increase in prepaid expenses, and a $523,440 increase in inventory.

cash used in operating activities was $4,691,290 for the year ended December 31, 2019, mainly related to the net loss of $11,312,500,

and offset by non-cash stock-based compensation of $7,482,254 related to various equity awards to employees and non-employees.

Company did not have any investing activities during the year ended December 31, 2020.

cash provided by investing activities was $4,915,236 for the year ended December 31, 2019, related to the cash acquired in the

reverse acquisition of $5,441,437, partially offset by advances to a shareholder of $199,549 and the purchase of Alliance convertible

notes receivable of $215,000 and capital expenditures of $111,652.

cash provided by financing activities was $847,542 for the year ended December 31, 2020, primarily related to $515,000 in proceeds

from equity financing and $293,972 in proceeds from a note payable.

cash provided by financing activities was $187,548 for the year ended December 31, 2019, primarily related to the proceeds from

a note payable, related party.

Cash Obligations

to Note 8, Commitments and Contingencies, in the accompanying consolidated financial statements for additional detail.

Sheet Arrangements

of December 31, 2020, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.

Quantitative and Qualitative Disclosures About Market Risk

are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity